These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

452 related articles for article (PubMed ID: 27249171)

  • 1. The ubiquitin E3 ligase TRAF6 exacerbates pathological cardiac hypertrophy via TAK1-dependent signalling.
    Ji YX; Zhang P; Zhang XJ; Zhao YC; Deng KQ; Jiang X; Wang PX; Huang Z; Li H
    Nat Commun; 2016 Jun; 7():11267. PubMed ID: 27249171
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phosphoinositide-dependent kinase-1 inhibits TRAF6 ubiquitination by interrupting the formation of TAK1-TAB2 complex in TLR4 signaling.
    Moon G; Kim J; Min Y; Wi SM; Shim JH; Chun E; Lee KY
    Cell Signal; 2015 Dec; 27(12):2524-33. PubMed ID: 26432169
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The type I TGF-beta receptor engages TRAF6 to activate TAK1 in a receptor kinase-independent manner.
    Sorrentino A; Thakur N; Grimsby S; Marcusson A; von Bulow V; Schuster N; Zhang S; Heldin CH; Landström M
    Nat Cell Biol; 2008 Oct; 10(10):1199-207. PubMed ID: 18758450
    [TBL] [Abstract][Full Text] [Related]  

  • 4. C1q-tumour necrosis factor-related protein-3 exacerbates cardiac hypertrophy in mice.
    Ma ZG; Yuan YP; Zhang X; Xu SC; Kong CY; Song P; Li N; Tang QZ
    Cardiovasc Res; 2019 May; 115(6):1067-1077. PubMed ID: 30407523
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Roles of the TRAF6 and Pellino E3 ligases in MyD88 and RANKL signaling.
    Strickson S; Emmerich CH; Goh ETH; Zhang J; Kelsall IR; Macartney T; Hastie CJ; Knebel A; Peggie M; Marchesi F; Arthur JSC; Cohen P
    Proc Natl Acad Sci U S A; 2017 Apr; 114(17):E3481-E3489. PubMed ID: 28404732
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cereblon negatively regulates TLR4 signaling through the attenuation of ubiquitination of TRAF6.
    Min Y; Wi SM; Kang JA; Yang T; Park CS; Park SG; Chung S; Shim JH; Chun E; Lee KY
    Cell Death Dis; 2016 Jul; 7(7):e2313. PubMed ID: 27468689
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Myricetin Alleviates Pathological Cardiac Hypertrophy via TRAF6/TAK1/MAPK and Nrf2 Signaling Pathway.
    Liao HH; Zhang N; Meng YY; Feng H; Yang JJ; Li WJ; Chen S; Wu HM; Deng W; Tang QZ
    Oxid Med Cell Longev; 2019; 2019():6304058. PubMed ID: 31885808
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Smad6 inhibits non-canonical TGF-β1 signalling by recruiting the deubiquitinase A20 to TRAF6.
    Jung SM; Lee JH; Park J; Oh YS; Lee SK; Park JS; Lee YS; Kim JH; Lee JY; Bae YS; Koo SH; Kim SJ; Park SH
    Nat Commun; 2013; 4():2562. PubMed ID: 24096742
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interleukin-1 and TRAF6-dependent activation of TAK1 in the absence of TAB2 and TAB3.
    Zhang J; Macartney T; Peggie M; Cohen P
    Biochem J; 2017 Jun; 474(13):2235-2248. PubMed ID: 28507161
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epigallocatechin-3-gallate(EGCG) suppresses melanoma cell growth and metastasis by targeting TRAF6 activity.
    Zhang J; Lei Z; Huang Z; Zhang X; Zhou Y; Luo Z; Zeng W; Su J; Peng C; Chen X
    Oncotarget; 2016 Nov; 7(48):79557-79571. PubMed ID: 27791197
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tripartite Motif 8 Contributes to Pathological Cardiac Hypertrophy Through Enhancing Transforming Growth Factor β-Activated Kinase 1-Dependent Signaling Pathways.
    Chen L; Huang J; Ji YX; Mei F; Wang PX; Deng KQ; Jiang X; Ma G; Li H
    Hypertension; 2017 Feb; 69(2):249-258. PubMed ID: 27956576
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FBXW5 acts as a negative regulator of pathological cardiac hypertrophy by decreasing the TAK1 signaling to pro-hypertrophic members of the MAPK signaling pathway.
    Hui X; Hu F; Liu J; Li C; Yang Y; Shu S; Liu P; Wang F; Li S
    J Mol Cell Cardiol; 2021 Feb; 151():31-43. PubMed ID: 32971071
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TAB2, TRAF6 and TAK1 are involved in NF-kappaB activation induced by the TNF-receptor, Edar and its adaptator Edaradd.
    Morlon A; Munnich A; Smahi A
    Hum Mol Genet; 2005 Dec; 14(23):3751-7. PubMed ID: 16251197
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemical inhibition of TRAF6-TAK1 axis as therapeutic strategy of endotoxin-induced liver disease.
    Kim SH; Baek SI; Jung J; Lee ES; Na Y; Hwang BY; Roh YS; Hong JT; Han SB; Kim Y
    Biomed Pharmacother; 2022 Nov; 155():113688. PubMed ID: 36150308
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Poxviral protein A52 stimulates p38 mitogen-activated protein kinase (MAPK) activation by causing tumor necrosis factor receptor-associated factor 6 (TRAF6) self-association leading to transforming growth factor β-activated kinase 1 (TAK1) recruitment.
    Stack J; Hurst TP; Flannery SM; Brennan K; Rupp S; Oda SI; Khan AR; Bowie AG
    J Biol Chem; 2013 Nov; 288(47):33642-33653. PubMed ID: 24114841
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TAK1-binding protein 2 facilitates ubiquitination of TRAF6 and assembly of TRAF6 with IKK in the IL-1 signaling pathway.
    Kishida S; Sanjo H; Akira S; Matsumoto K; Ninomiya-Tsuji J
    Genes Cells; 2005 May; 10(5):447-54. PubMed ID: 15836773
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oligomerization-primed coiled-coil domain interaction with Ubc13 confers processivity to TRAF6 ubiquitin ligase activity.
    Hu L; Xu J; Xie X; Zhou Y; Tao P; Li H; Han X; Wang C; Liu J; Xu P; Neculai D; Xia Z
    Nat Commun; 2017 Oct; 8(1):814. PubMed ID: 28993672
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The tyrosine kinase Syk differentially regulates Toll-like receptor signaling downstream of the adaptor molecules TRAF6 and TRAF3.
    Lin YC; Huang DY; Chu CL; Lin YL; Lin WW
    Sci Signal; 2013 Aug; 6(289):ra71. PubMed ID: 23962979
    [TBL] [Abstract][Full Text] [Related]  

  • 19. RNF207 exacerbates pathological cardiac hypertrophy via post-translational modification of TAB1.
    Yuan L; Bu S; Du M; Wang Y; Ju C; Huang D; Xu W; Tan X; Liang M; Deng S; Yang L; Huang K
    Cardiovasc Res; 2023 Mar; 119(1):183-194. PubMed ID: 35352799
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ubiquitin-specific protease 19 blunts pathological cardiac hypertrophy via inhibition of the TAK1-dependent pathway.
    Miao R; Lu Y; He X; Liu X; Chen Z; Wang J
    J Cell Mol Med; 2020 Sep; 24(18):10946-10957. PubMed ID: 32798288
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.